This week's Brexit downsides: half a billion in extra costs to import food, the collapse of trade talks with Canada and more.

As obvious as it is to see the decline in the number of clinical trials in the UK, the reasons behind this trend are as complicated to ascertain. Fiona Maini, Principal - Global Compliance and Strategy at Medidata Solutions, thinks the issue is multifaced with Brexit playing a part in this.

The UK left the EU on January 31, 2020, and this began the complex process of de-coupling the UK regulatory regime from that of the EU. This has not been straightforward, particularly where goods move into and out of Northern Ireland (NI), where the EU rules continue to apply, from Great Britain (England, Wales, and Scotland (GB)), where they do not.

On 1 August 2023, the UK Government announced an “indefinite” extension to the recognition of CE marking for certain products placed on the market in Great Britain.

Helmuth Porschen ponders the fate of UKCA and wonders why the government can’t persuade the rest of the world to adopt British standards.

In the latest Brexit step-down, many goods will now have indefinite CE mark recognition – but MHRA keeps 2028 and 2030 cut-offs for medical devices.

Preparedness and vaccine rollout outside of EU under scrutiny as inquiry kicks off.

Boris Johnson has faced the wrath of social media for posting a video banging on about Brexit.

On the third anniversary of Brexit, Boris Johnson has attempted to paint the withdrawal from the EU as a major boost for the UK – but immediately faced pushback over a questionable claim.

A House of Lords committee will discuss the impact of the Northern Ireland protocol on medicine supplies in Northern Ireland.

Specialisms such as dentistry have shortages and EU exit still causes issues with medicines in Northern Ireland, thinktank finds.

There are growing post-Brexit differences between which medicines are approved for use in Northern Ireland and the rest of the UK, research from a health think tank indicates.

With the exception of the very lowest risk devices, manufacturers must apply to a UK approved body. Only after they have UKCA certification can their products be placed on the market in England, Wales and Scotland.

As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

BREXIT is causing “damage across the board” to UK science, including missing out on more than £1 billion in funding, campaigners have warned.

There are a number of measures that the UK Government must take in order to address the challenges of leaving the EU's single market.

The UK’s medicines and devices regulator will stop work that “does not add value” and lose over 100 full time equivalent staff posts as part of its post-Brexit cost cutting drive, a leaked consultation document seen by The BMJ shows. / But experts warned that plans to streamline regulation to speed up the development and approval of new drugs for patients’ benefit carried potential safety risks.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

UK drug distributors and those involved in the parallel importing of drugs have told the parliamentary Health Select Committee that they want to see the UK remain in the customs union and the single market.

A new video by Peter Stefanovic rubbished Johnson's claim that the vaccine rollout's success was down to Brexit.

Informa Pharma Intelligence (IPI) has found that some drug firms may withdraw up to 90% of their products from Northern Ireland, once the Brexit grace period has passed.

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions.

The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income due to reduced medical product submissions following Brexit, spurring anger among unions across the island.